依达拉奉联合低分子肝素治疗急性进展性脑梗死的临床研究

目的探讨依达拉奉联合低分子肝素治疗急性进展性脑梗死的临床疗效。方法选取本院2009年11月～2011年12月收治的急性进展性脑梗死患者76例,将其随机分为两组,38例患者使用低分子肝素作为对照组,38例患者采用依达拉奉联合低分子肝素作为观察组,分析两组患者的临床指标,并进行神经功能缺损程度评分。结果观察组患者的活化部分凝血活酶时间为（32.5±7.1）s,长于对照组的（31.0±6.2）s,两组差异无统计学意义（P〉0.05）。观察组患者的血小板计数为（184.2±29.6）×109/L、总有效率为76.3%,均明显高于对照组的（146.7±31.4）×109/L、52.6%,观察组纤维蛋白原水平为（2.9±0.7）g/L、神经元特异性烯醇化酶水平为（10.7±2.9）μg/L、神经功能缺损程度评分为（10.7±2.8）分,均明显低于对照组的（3.3±1.4）g/L、（21.6±4.1）μg/L、（18.2±4.6）分,两组差异均有统计学意义（P〈0.05）。结论依达拉奉联合低分子肝素治疗急性进展性脑梗死可显著改善患者的神经功能,且安全有效。

Clinical study on edaravone and low molecular weight heparin in the treatment of acute progressive cerebral infarction

Objective To investigate the clinical efficacy of edaravone and low molecular weight heparin in the treatment of acute progressive cerebral infarction. Methods Seventy-six patients with acute progressive cerebral infarction were selected in the hospital from November 2009 to December 2011, who were randomly divided into two groups. 38 patients used low molecular weight heparin in the treatment as the control group, 38 patients used edaravone and low molecular weight heparin in the treatment as the observation group. Clinical indicators and the scores of neurological deficit were compared between two groups after treatment. Results Activated partial thromboplastin time in the observation group was (32.5±7.1) s, which was longer than (31.0±6.2) s in the control group, while the difference was not statistically significant (P > 0.05). Platelet counts and the total efficiency in the observation group were (184.2±29.6)×109/L and 76.3%, respectively, which were significantly higher than (146.7±31.4)×109/L and 52.6% in the control group. Fibrinogen level, neuron specific enolase levels, the scores of neurological deficit in the observation group were (2.9±0.7) g/L, (10.7±2.9) μg/L, (10.7±2.8), respectively, which were significantly lower than (3.3±1.4) g/L, (21.6±4.1) μg/L, (18.2±4.6) in the control group. The differences were statistically significant (P < 0.05). Conclusion Edaravone and low molecular weight heparin in the treatment of acute progressive cerebral infarction can obviously improve the neurological function, which is safe and effective.